Propanc Biopharma, Inc. (PPCB)
OTCMKTS · Delayed Price · Currency is USD
5.25
-0.25 (-4.55%)
Apr 4, 2025, 2:39 PM EST

Propanc Biopharma Company Description

Propanc Biopharma, Inc., a biopharmaceutical company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia.

Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies.

The company has a research collaboration with University of Jaén to carry out a research project aimed at the synthetic development of PRP and its subsequent validation; and a joint research and drug discovery program with Universities of Jaén and Granada for the POP1 program to investigate the changes in genetic and protein expression that occur in cancer cells.

The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017.

Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.

Propanc Biopharma, Inc.
Propanc Biopharma logo
Country United States
Founded 2007
Industry Biotechnology
Sector Healthcare
Employees 2
CEO James Nathanielsz

Contact Details

Address:
302, 6 Butler Street
Camberwell, Delaware 3124
Australia
Phone 61 3 9882 0780
Website propanc.com

Stock Details

Ticker Symbol PPCB
Exchange OTCMKTS
Stock Type Common Stock
Fiscal Year July - June
Reporting Currency USD
ISIN Number US74346N4043
SIC Code 2836

Key Executives

Name Position
James Nathanielsz Executive Chairman, Chief Executive Officer, Chief Financial Officer, Treasurer and Secretary
Dr. Julian Norman Kenyon ChB, M.D., MB Chief Scientific Officer, Chief Technology Officer and Director
Prof. Klaus Kutz M.D. Chief Medical Officer and Member of Scientific Advisory Board